Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $12.42 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.82, a 20.56% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $14.88, a 17.17% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.70, a 6.69% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $13.61, a 5.68% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $14.53, a 5.21% increase from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $13.81, a 10.32% decline from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $15.40, a 5.77% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $14.56, a 4.37% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.42 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $11.82 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $14.53 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $14.50 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $14.49 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $14.88 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $13.81 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $13.66 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $13.27 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $12.70 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | $15.40 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $15.27 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $15.22 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $13.61 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $14.56 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $14.70 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $14.62 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $14.43 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $13.95 10-K · filed 2022-03-11 | |||
| 2021-09-30 | $13.49 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $13.87 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $12.64 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $13.96 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $14.03 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $14.22 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $14.18 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $15.10 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $15.14 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $15.60 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $15.60 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $13.14 10-K · filed 2019-03-15 | |||
| 2018-09-30 | $12.32 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $12.55 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $12.61 10-Q · filed 2018-05-10 | |||
| 2017-12-31 | $11.80 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $11.60 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $11.61 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | $11.87 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | $13.88 10-K · filed 2017-03-15 | |||
| 2016-09-30 | $13.93 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $11.61 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $11.31 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $13.06 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $13.32 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $13.43 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $12.55 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $10.79 10-K · filed 2016-03-15 | |||
| 2014-09-30 | $10.79 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $19.03 10-Q · filed 2014-08-13 | |||
| 2013-12-31 | $13.07 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |